nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Fludarabine—lymphatic system cancer	0.296	0.514	CrCtD
Vidarabine—Cytarabine—lymphatic system cancer	0.28	0.486	CrCtD
Vidarabine—Glucosamine—Cytarabine—lymphatic system cancer	0.0285	0.0716	CrCrCtD
Vidarabine—Adenosine triphosphate—Fludarabine—lymphatic system cancer	0.0227	0.057	CrCrCtD
Vidarabine—Ribavirin—Fludarabine—lymphatic system cancer	0.021	0.0528	CrCrCtD
Vidarabine—Ribavirin—Cytarabine—lymphatic system cancer	0.0198	0.0499	CrCrCtD
Vidarabine—Regadenoson—Fludarabine—lymphatic system cancer	0.0196	0.0493	CrCrCtD
Vidarabine—S-Adenosylmethionine—Fludarabine—lymphatic system cancer	0.0196	0.0493	CrCrCtD
Vidarabine—Clofarabine—Fludarabine—lymphatic system cancer	0.0196	0.0493	CrCrCtD
Vidarabine—S-Adenosylmethionine—Cytarabine—lymphatic system cancer	0.0185	0.0466	CrCrCtD
Vidarabine—Clofarabine—Cytarabine—lymphatic system cancer	0.0185	0.0466	CrCrCtD
Vidarabine—Regadenoson—Cytarabine—lymphatic system cancer	0.0185	0.0466	CrCrCtD
Vidarabine—Fludarabine—Cytarabine—lymphatic system cancer	0.0173	0.0437	CrCrCtD
Vidarabine—Nelarabine—Fludarabine—lymphatic system cancer	0.0173	0.0436	CrCrCtD
Vidarabine—Adenosine monophosphate—Fludarabine—lymphatic system cancer	0.0173	0.0436	CrCrCtD
Vidarabine—Cytarabine—Fludarabine—lymphatic system cancer	0.0164	0.0412	CrCrCtD
Vidarabine—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.0163	0.0412	CrCrCtD
Vidarabine—Nelarabine—Cytarabine—lymphatic system cancer	0.0163	0.0412	CrCrCtD
Vidarabine—Adenosine—Fludarabine—lymphatic system cancer	0.0156	0.0392	CrCrCtD
Vidarabine—Cladribine—Fludarabine—lymphatic system cancer	0.0156	0.0392	CrCrCtD
Vidarabine—Azacitidine—Fludarabine—lymphatic system cancer	0.0156	0.0392	CrCrCtD
Vidarabine—Adenosine—Cytarabine—lymphatic system cancer	0.0147	0.037	CrCrCtD
Vidarabine—Azacitidine—Cytarabine—lymphatic system cancer	0.0147	0.037	CrCrCtD
Vidarabine—Decitabine—Cytarabine—lymphatic system cancer	0.014	0.0352	CrCrCtD
Vidarabine—Adenosine triphosphate—ALK—lymphatic system cancer	0.00105	1	CrCbGaD
Vidarabine—Tonic-clonic seizures—Carmustine—lymphatic system cancer	0.000918	0.0359	CcSEcCtD
Vidarabine—Coronary artery disease—Vincristine—lymphatic system cancer	0.000597	0.0233	CcSEcCtD
Vidarabine—Intracranial pressure increased—Carmustine—lymphatic system cancer	0.000592	0.0231	CcSEcCtD
Vidarabine—Haemorrhage intracranial—Mitoxantrone—lymphatic system cancer	0.00056	0.0219	CcSEcCtD
Vidarabine—Grand mal convulsion—Carmustine—lymphatic system cancer	0.000519	0.0203	CcSEcCtD
Vidarabine—Numbness—Fludarabine—lymphatic system cancer	0.000466	0.0182	CcSEcCtD
Vidarabine—Sensory loss—Fludarabine—lymphatic system cancer	0.000446	0.0174	CcSEcCtD
Vidarabine—Respiratory failure—Fludarabine—lymphatic system cancer	0.000393	0.0154	CcSEcCtD
Vidarabine—Taste metallic—Methotrexate—lymphatic system cancer	0.00036	0.0141	CcSEcCtD
Vidarabine—Burning sensation—Carmustine—lymphatic system cancer	0.000356	0.0139	CcSEcCtD
Vidarabine—Scotoma—Carmustine—lymphatic system cancer	0.000326	0.0127	CcSEcCtD
Vidarabine—Cardiac failure—Fludarabine—lymphatic system cancer	0.000287	0.0112	CcSEcCtD
Vidarabine—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.000286	0.0112	CcSEcCtD
Vidarabine—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.000286	0.0112	CcSEcCtD
Vidarabine—Numbness—Vincristine—lymphatic system cancer	0.000285	0.0111	CcSEcCtD
Vidarabine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.000279	0.0109	CcSEcCtD
Vidarabine—Sensory loss—Vincristine—lymphatic system cancer	0.000272	0.0107	CcSEcCtD
Vidarabine—Bronchospasm—Teniposide—lymphatic system cancer	0.000271	0.0106	CcSEcCtD
Vidarabine—Injection site reaction—Carmustine—lymphatic system cancer	0.000246	0.00961	CcSEcCtD
Vidarabine—Respiratory failure—Vincristine—lymphatic system cancer	0.00024	0.0094	CcSEcCtD
Vidarabine—Sweating—Teniposide—lymphatic system cancer	0.000236	0.00922	CcSEcCtD
Vidarabine—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.000213	0.00833	CcSEcCtD
Vidarabine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.000213	0.00832	CcSEcCtD
Vidarabine—Myocardial infarction—Fludarabine—lymphatic system cancer	0.000212	0.00828	CcSEcCtD
Vidarabine—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00021	0.0082	CcSEcCtD
Vidarabine—Flushing—Teniposide—lymphatic system cancer	0.000205	0.00801	CcSEcCtD
Vidarabine—Arrhythmia—Teniposide—lymphatic system cancer	0.000197	0.00771	CcSEcCtD
Vidarabine—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.000193	0.00755	CcSEcCtD
Vidarabine—Agitation—Teniposide—lymphatic system cancer	0.000177	0.0069	CcSEcCtD
Vidarabine—Bronchospasm—Bleomycin—lymphatic system cancer	0.000175	0.00683	CcSEcCtD
Vidarabine—Arrhythmia—Fludarabine—lymphatic system cancer	0.000173	0.00678	CcSEcCtD
Vidarabine—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.000171	0.00668	CcSEcCtD
Vidarabine—Hypertension—Teniposide—lymphatic system cancer	0.000166	0.00649	CcSEcCtD
Vidarabine—Burning sensation—Methotrexate—lymphatic system cancer	0.000165	0.00645	CcSEcCtD
Vidarabine—Chest pain—Teniposide—lymphatic system cancer	0.000164	0.0064	CcSEcCtD
Vidarabine—Cardiac arrest—Vincristine—lymphatic system cancer	0.000163	0.00637	CcSEcCtD
Vidarabine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000157	0.00613	CcSEcCtD
Vidarabine—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.000156	0.00611	CcSEcCtD
Vidarabine—Myocardial infarction—Bleomycin—lymphatic system cancer	0.000155	0.00607	CcSEcCtD
Vidarabine—Agitation—Fludarabine—lymphatic system cancer	0.000155	0.00607	CcSEcCtD
Vidarabine—Tachycardia—Teniposide—lymphatic system cancer	0.000153	0.00598	CcSEcCtD
Vidarabine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000152	0.00593	CcSEcCtD
Vidarabine—Cough—Fludarabine—lymphatic system cancer	0.000147	0.00576	CcSEcCtD
Vidarabine—Hypotension—Teniposide—lymphatic system cancer	0.000147	0.00573	CcSEcCtD
Vidarabine—Convulsion—Fludarabine—lymphatic system cancer	0.000146	0.00572	CcSEcCtD
Vidarabine—Discomfort—Fludarabine—lymphatic system cancer	0.000142	0.00555	CcSEcCtD
Vidarabine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.000142	0.00553	CcSEcCtD
Vidarabine—Dyspnoea—Teniposide—lymphatic system cancer	0.00014	0.00547	CcSEcCtD
Vidarabine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000138	0.00539	CcSEcCtD
Vidarabine—Vomiting—Mechlorethamine—lymphatic system cancer	0.000135	0.00529	CcSEcCtD
Vidarabine—Apnoea—Methotrexate—lymphatic system cancer	0.000135	0.00528	CcSEcCtD
Vidarabine—Rash—Mechlorethamine—lymphatic system cancer	0.000134	0.00524	CcSEcCtD
Vidarabine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000134	0.00524	CcSEcCtD
Vidarabine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000133	0.00521	CcSEcCtD
Vidarabine—Flushing—Bleomycin—lymphatic system cancer	0.000132	0.00516	CcSEcCtD
Vidarabine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00013	0.00509	CcSEcCtD
Vidarabine—Myocardial infarction—Vincristine—lymphatic system cancer	0.000129	0.00506	CcSEcCtD
Vidarabine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000129	0.00503	CcSEcCtD
Vidarabine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000127	0.00496	CcSEcCtD
Vidarabine—Sweating—Vincristine—lymphatic system cancer	0.000127	0.00495	CcSEcCtD
Vidarabine—Nausea—Mechlorethamine—lymphatic system cancer	0.000126	0.00494	CcSEcCtD
Vidarabine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000126	0.00493	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000126	0.00491	CcSEcCtD
Vidarabine—Urticaria—Teniposide—lymphatic system cancer	0.000125	0.00487	CcSEcCtD
Vidarabine—Paraesthesia—Fludarabine—lymphatic system cancer	0.000124	0.00484	CcSEcCtD
Vidarabine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000124	0.00483	CcSEcCtD
Vidarabine—Sweating—Mitoxantrone—lymphatic system cancer	0.000123	0.00482	CcSEcCtD
Vidarabine—Dyspnoea—Fludarabine—lymphatic system cancer	0.000123	0.0048	CcSEcCtD
Vidarabine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000118	0.00461	CcSEcCtD
Vidarabine—Pain—Fludarabine—lymphatic system cancer	0.000118	0.00461	CcSEcCtD
Vidarabine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000117	0.00459	CcSEcCtD
Vidarabine—Respiratory failure—Methotrexate—lymphatic system cancer	0.000117	0.00456	CcSEcCtD
Vidarabine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000116	0.00452	CcSEcCtD
Vidarabine—Flushing—Carmustine—lymphatic system cancer	0.000115	0.00451	CcSEcCtD
Vidarabine—Asthenia—Teniposide—lymphatic system cancer	0.000112	0.0044	CcSEcCtD
Vidarabine—Arrhythmia—Carmustine—lymphatic system cancer	0.000111	0.00434	CcSEcCtD
Vidarabine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00011	0.0043	CcSEcCtD
Vidarabine—Cough—Bleomycin—lymphatic system cancer	0.000108	0.00422	CcSEcCtD
Vidarabine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000107	0.00418	CcSEcCtD
Vidarabine—Chest pain—Bleomycin—lymphatic system cancer	0.000105	0.00412	CcSEcCtD
Vidarabine—Back pain—Carmustine—lymphatic system cancer	0.000105	0.00409	CcSEcCtD
Vidarabine—Discomfort—Bleomycin—lymphatic system cancer	0.000104	0.00407	CcSEcCtD
Vidarabine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000103	0.00403	CcSEcCtD
Vidarabine—Vision blurred—Carmustine—lymphatic system cancer	0.000102	0.00398	CcSEcCtD
Vidarabine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000102	0.00397	CcSEcCtD
Vidarabine—Tremor—Carmustine—lymphatic system cancer	0.000101	0.00396	CcSEcCtD
Vidarabine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000101	0.00395	CcSEcCtD
Vidarabine—Back pain—Vincristine—lymphatic system cancer	9.98e-05	0.0039	CcSEcCtD
Vidarabine—Vomiting—Teniposide—lymphatic system cancer	9.97e-05	0.0039	CcSEcCtD
Vidarabine—Agitation—Carmustine—lymphatic system cancer	9.93e-05	0.00388	CcSEcCtD
Vidarabine—Asthenia—Fludarabine—lymphatic system cancer	9.89e-05	0.00387	CcSEcCtD
Vidarabine—Rash—Teniposide—lymphatic system cancer	9.89e-05	0.00387	CcSEcCtD
Vidarabine—Dermatitis—Teniposide—lymphatic system cancer	9.88e-05	0.00386	CcSEcCtD
Vidarabine—Dysgeusia—Mitoxantrone—lymphatic system cancer	9.84e-05	0.00385	CcSEcCtD
Vidarabine—Headache—Teniposide—lymphatic system cancer	9.82e-05	0.00384	CcSEcCtD
Vidarabine—Back pain—Mitoxantrone—lymphatic system cancer	9.72e-05	0.0038	CcSEcCtD
Vidarabine—Agitation—Vincristine—lymphatic system cancer	9.48e-05	0.00371	CcSEcCtD
Vidarabine—Vision blurred—Mitoxantrone—lymphatic system cancer	9.47e-05	0.0037	CcSEcCtD
Vidarabine—Hypotension—Bleomycin—lymphatic system cancer	9.44e-05	0.00369	CcSEcCtD
Vidarabine—Convulsion—Carmustine—lymphatic system cancer	9.36e-05	0.00366	CcSEcCtD
Vidarabine—Hypertension—Carmustine—lymphatic system cancer	9.33e-05	0.00365	CcSEcCtD
Vidarabine—Nausea—Teniposide—lymphatic system cancer	9.31e-05	0.00364	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	9.21e-05	0.0036	CcSEcCtD
Vidarabine—Chest pain—Carmustine—lymphatic system cancer	9.2e-05	0.0036	CcSEcCtD
Vidarabine—Anxiety—Carmustine—lymphatic system cancer	9.17e-05	0.00359	CcSEcCtD
Vidarabine—Paraesthesia—Bleomycin—lymphatic system cancer	9.07e-05	0.00355	CcSEcCtD
Vidarabine—Dyspnoea—Bleomycin—lymphatic system cancer	9.01e-05	0.00352	CcSEcCtD
Vidarabine—Convulsion—Vincristine—lymphatic system cancer	8.94e-05	0.0035	CcSEcCtD
Vidarabine—Hypertension—Vincristine—lymphatic system cancer	8.91e-05	0.00348	CcSEcCtD
Vidarabine—Cough—Mitoxantrone—lymphatic system cancer	8.77e-05	0.00343	CcSEcCtD
Vidarabine—Vomiting—Fludarabine—lymphatic system cancer	8.76e-05	0.00343	CcSEcCtD
Vidarabine—Convulsion—Mitoxantrone—lymphatic system cancer	8.7e-05	0.0034	CcSEcCtD
Vidarabine—Rash—Fludarabine—lymphatic system cancer	8.69e-05	0.0034	CcSEcCtD
Vidarabine—Dermatitis—Fludarabine—lymphatic system cancer	8.68e-05	0.00339	CcSEcCtD
Vidarabine—Hypertension—Mitoxantrone—lymphatic system cancer	8.67e-05	0.00339	CcSEcCtD
Vidarabine—Pain—Bleomycin—lymphatic system cancer	8.64e-05	0.00338	CcSEcCtD
Vidarabine—Headache—Fludarabine—lymphatic system cancer	8.63e-05	0.00338	CcSEcCtD
Vidarabine—Tachycardia—Carmustine—lymphatic system cancer	8.61e-05	0.00337	CcSEcCtD
Vidarabine—Chest pain—Mitoxantrone—lymphatic system cancer	8.55e-05	0.00334	CcSEcCtD
Vidarabine—Anxiety—Mitoxantrone—lymphatic system cancer	8.52e-05	0.00333	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	8.48e-05	0.00332	CcSEcCtD
Vidarabine—Discomfort—Mitoxantrone—lymphatic system cancer	8.45e-05	0.0033	CcSEcCtD
Vidarabine—Anaphylactic shock—Vincristine—lymphatic system cancer	8.42e-05	0.00329	CcSEcCtD
Vidarabine—Hypotension—Carmustine—lymphatic system cancer	8.24e-05	0.00322	CcSEcCtD
Vidarabine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	8.2e-05	0.00321	CcSEcCtD
Vidarabine—Nausea—Fludarabine—lymphatic system cancer	8.19e-05	0.0032	CcSEcCtD
Vidarabine—Hyperhidrosis—Vincristine—lymphatic system cancer	8.14e-05	0.00318	CcSEcCtD
Vidarabine—Shock—Mitoxantrone—lymphatic system cancer	8.07e-05	0.00315	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	8.04e-05	0.00314	CcSEcCtD
Vidarabine—Urticaria—Bleomycin—lymphatic system cancer	8.03e-05	0.00314	CcSEcCtD
Vidarabine—Tachycardia—Mitoxantrone—lymphatic system cancer	8e-05	0.00313	CcSEcCtD
Vidarabine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	7.93e-05	0.0031	CcSEcCtD
Vidarabine—Paraesthesia—Carmustine—lymphatic system cancer	7.92e-05	0.0031	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—lymphatic system cancer	7.87e-05	0.00308	CcSEcCtD
Vidarabine—Hypotension—Vincristine—lymphatic system cancer	7.87e-05	0.00308	CcSEcCtD
Vidarabine—Dyspnoea—Carmustine—lymphatic system cancer	7.86e-05	0.00307	CcSEcCtD
Vidarabine—Somnolence—Carmustine—lymphatic system cancer	7.84e-05	0.00307	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	7.67e-05	0.003	CcSEcCtD
Vidarabine—Hypotension—Mitoxantrone—lymphatic system cancer	7.66e-05	0.003	CcSEcCtD
Vidarabine—Paraesthesia—Vincristine—lymphatic system cancer	7.56e-05	0.00296	CcSEcCtD
Vidarabine—Pain—Carmustine—lymphatic system cancer	7.54e-05	0.00295	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	7.47e-05	0.00292	CcSEcCtD
Vidarabine—Hypersensitivity—Bleomycin—lymphatic system cancer	7.44e-05	0.00291	CcSEcCtD
Vidarabine—Paraesthesia—Mitoxantrone—lymphatic system cancer	7.36e-05	0.00288	CcSEcCtD
Vidarabine—Dyspnoea—Mitoxantrone—lymphatic system cancer	7.31e-05	0.00286	CcSEcCtD
Vidarabine—Somnolence—Mitoxantrone—lymphatic system cancer	7.29e-05	0.00285	CcSEcCtD
Vidarabine—Asthenia—Bleomycin—lymphatic system cancer	7.25e-05	0.00283	CcSEcCtD
Vidarabine—Pain—Vincristine—lymphatic system cancer	7.2e-05	0.00282	CcSEcCtD
Vidarabine—Pain—Mitoxantrone—lymphatic system cancer	7.01e-05	0.00274	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—lymphatic system cancer	6.89e-05	0.00269	CcSEcCtD
Vidarabine—Urticaria—Mitoxantrone—lymphatic system cancer	6.51e-05	0.00255	CcSEcCtD
Vidarabine—Hypersensitivity—Carmustine—lymphatic system cancer	6.5e-05	0.00254	CcSEcCtD
Vidarabine—Vomiting—Bleomycin—lymphatic system cancer	6.42e-05	0.00251	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—lymphatic system cancer	6.41e-05	0.0025	CcSEcCtD
Vidarabine—Rash—Bleomycin—lymphatic system cancer	6.37e-05	0.00249	CcSEcCtD
Vidarabine—Dermatitis—Bleomycin—lymphatic system cancer	6.36e-05	0.00249	CcSEcCtD
Vidarabine—Asthenia—Carmustine—lymphatic system cancer	6.33e-05	0.00247	CcSEcCtD
Vidarabine—Hypersensitivity—Vincristine—lymphatic system cancer	6.2e-05	0.00243	CcSEcCtD
Vidarabine—Sweating—Methotrexate—lymphatic system cancer	6.14e-05	0.0024	CcSEcCtD
Vidarabine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	6.04e-05	0.00236	CcSEcCtD
Vidarabine—Asthenia—Vincristine—lymphatic system cancer	6.04e-05	0.00236	CcSEcCtD
Vidarabine—Nausea—Bleomycin—lymphatic system cancer	6e-05	0.00235	CcSEcCtD
Vidarabine—Asthenia—Mitoxantrone—lymphatic system cancer	5.88e-05	0.0023	CcSEcCtD
Vidarabine—Dizziness—Carmustine—lymphatic system cancer	5.83e-05	0.00228	CcSEcCtD
Vidarabine—Vomiting—Carmustine—lymphatic system cancer	5.61e-05	0.00219	CcSEcCtD
Vidarabine—Dizziness—Vincristine—lymphatic system cancer	5.57e-05	0.00218	CcSEcCtD
Vidarabine—Rash—Carmustine—lymphatic system cancer	5.56e-05	0.00217	CcSEcCtD
Vidarabine—Dermatitis—Carmustine—lymphatic system cancer	5.56e-05	0.00217	CcSEcCtD
Vidarabine—Headache—Carmustine—lymphatic system cancer	5.53e-05	0.00216	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—lymphatic system cancer	5.36e-05	0.0021	CcSEcCtD
Vidarabine—Vomiting—Vincristine—lymphatic system cancer	5.35e-05	0.00209	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—lymphatic system cancer	5.34e-05	0.00209	CcSEcCtD
Vidarabine—Rash—Vincristine—lymphatic system cancer	5.31e-05	0.00208	CcSEcCtD
Vidarabine—Dermatitis—Vincristine—lymphatic system cancer	5.3e-05	0.00207	CcSEcCtD
Vidarabine—Headache—Vincristine—lymphatic system cancer	5.27e-05	0.00206	CcSEcCtD
Vidarabine—Nausea—Carmustine—lymphatic system cancer	5.24e-05	0.00205	CcSEcCtD
Vidarabine—Vomiting—Mitoxantrone—lymphatic system cancer	5.21e-05	0.00204	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—lymphatic system cancer	5.18e-05	0.00203	CcSEcCtD
Vidarabine—Rash—Mitoxantrone—lymphatic system cancer	5.17e-05	0.00202	CcSEcCtD
Vidarabine—Dermatitis—Mitoxantrone—lymphatic system cancer	5.16e-05	0.00202	CcSEcCtD
Vidarabine—Headache—Mitoxantrone—lymphatic system cancer	5.14e-05	0.00201	CcSEcCtD
Vidarabine—Nausea—Vincristine—lymphatic system cancer	5e-05	0.00196	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—lymphatic system cancer	4.9e-05	0.00192	CcSEcCtD
Vidarabine—Nausea—Mitoxantrone—lymphatic system cancer	4.87e-05	0.0019	CcSEcCtD
Vidarabine—Back pain—Methotrexate—lymphatic system cancer	4.84e-05	0.00189	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—lymphatic system cancer	4.72e-05	0.00184	CcSEcCtD
Vidarabine—Cough—Methotrexate—lymphatic system cancer	4.37e-05	0.00171	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—lymphatic system cancer	4.34e-05	0.0017	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—lymphatic system cancer	4.26e-05	0.00167	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—lymphatic system cancer	4.21e-05	0.00165	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—lymphatic system cancer	4.09e-05	0.0016	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—lymphatic system cancer	3.95e-05	0.00154	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—lymphatic system cancer	3.82e-05	0.00149	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	3.72e-05	0.00146	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—lymphatic system cancer	3.67e-05	0.00143	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—lymphatic system cancer	3.64e-05	0.00142	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—lymphatic system cancer	3.63e-05	0.00142	CcSEcCtD
Vidarabine—Pain—Methotrexate—lymphatic system cancer	3.49e-05	0.00137	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—lymphatic system cancer	3.25e-05	0.00127	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—lymphatic system cancer	3.01e-05	0.00118	CcSEcCtD
Vidarabine—Asthenia—Methotrexate—lymphatic system cancer	2.93e-05	0.00115	CcSEcCtD
Vidarabine—Dizziness—Methotrexate—lymphatic system cancer	2.7e-05	0.00106	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—lymphatic system cancer	2.6e-05	0.00102	CcSEcCtD
Vidarabine—Rash—Methotrexate—lymphatic system cancer	2.58e-05	0.00101	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—lymphatic system cancer	2.57e-05	0.00101	CcSEcCtD
Vidarabine—Headache—Methotrexate—lymphatic system cancer	2.56e-05	0.001	CcSEcCtD
Vidarabine—Nausea—Methotrexate—lymphatic system cancer	2.43e-05	0.000949	CcSEcCtD
